GTR Home > Tests > Breast Tumors Gene Set

Overview

Test name

Help

Breast Tumors Gene Set

Purpose of the test

Help

This is a clinical test intended for Help: Diagnosis, Prognostic, Therapeutic management

Condition

Help

2 conditions tested. Click Indication tab for more information.

Methodology

Help
Molecular Genetics
CSequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)

Summary of what is tested

42 genes and variants. Click Methodology tab for more information.

Genes

Clinical validity

Help

Not provided

Clinical utility

Help

Not provided

How to order

Help

To order a test, complete and submit a requisition form that can be found on our website (gps.wustl.edu)
Order URL Help: https://gps.wustl.edu/patient-care/forms-and-resources/

Test services

Help
  • Clinical Testing/Confirmation of Mutations Identified Previously

Suggested reading

  • Cardoso et al., 2016
  • Ward et al., 2013
    Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Practice guidelines

  • NCCBP, 2015
    Updated UK Recommendations for HER2 assessment in breast cancer.
  • ASCO, 2014
    Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.
  • ASCO, 2014
    Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
  • ASCO/CAP, 2014
    Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
  • NCCN, 2014
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast Cancer
  • USPSTF, 2013
    Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.
  • ESMO, 2013
    Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
  • NICE, 2013
    DG10 Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat: information for the public
  • St Gallen, 2013
    Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
  • ASCO, 2013
    Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
  • NSGC, 2013
    NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer.
  • AHRQ, 2013
    Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin
  • EGAPP, 2009
    Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
  • NACB, 2008
    National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
  • ASCO, 2007
    American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
  • Link text is missing.
    National Institute for Health and Care Excellence. Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. NICE diagnostics guidance 10 www.nice.org.uk/dg10, 2013.
  • Link text is missing.
    National Institute for Health and Care Excellence. Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. NICE diagnostics guidance 10. https://www.nice.org.uk/guidance/dg10.
  • NCCN, 2011
    National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology™: Breast cancer. Version 2.2011. Available at: www.nccn.org. Accessed September 29, 2011.
  • NCCN, 2011
    NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Support Center